Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 4 of 6
A Smartphone Intervention for Relational and Mental Well Being
University of Washington
NCT04629755
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Eli Lilly and Company
NCT04634409
Equitable Access to COVID-19 Vaccines
Mayo Clinic
NCT04952376
Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
Aetion
NCT05638932
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
BioNTech SE
NCT05004181
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
University of Minnesota
NCT04510194
COVID-19 Self-testing IMPROVE
Temple University
NCT06576167
Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing
The University of Texas Health Science Center, Houston
NCT05606016
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
Susanna Naggie, MD
NCT05894564
Social Activity, Loneliness and Stigma During COVID-19 Outbreak
Columbia University
NCT04734171
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
Eli Lilly and Company
NCT04497987
Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic
Washington University School of Medicine
NCT04565509
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
NCT05997290
The Safer At School Early Alert HUB
University of California, San Diego
NCT05642000
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
BioNTech SE
NCT05596734
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04640168
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04492475
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Romark Laboratories L.C.
NCT04486313
Vitamin D3 Supplementation to Prevent Respiratory Tract Infections
The Cooper Health System
NCT04596657
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
Epividian
NCT05104359
The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
National Bureau of Economic Research
NCT04644328
Social Determinants of Health in Patients With Penetrating Trauma Injuries Before and During the COVID-19 Pandemic
Kern Medical Center
NCT06135610
Views on COVID-19 and Vaccination
University of Massachusetts, Worcester
NCT04706403
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04761822
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
Corewell Health East
NCT04829552
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Novavax
NCT05975060
Getting INFORMED and Living Well Among Asian Americans in California
University of California, San Francisco
NCT05968300
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
Duke University
NCT04437706
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
University of Minnesota
NCT04546581
Minnesota COVID-19 Testing Project
Harvard University
NCT04568889
COVID-19 Treatment Cascade Optimization Study
University of Illinois at Urbana-Champaign
NCT05305443
Convalescent Plasma in Outpatients With COVID-19
Stanford University
NCT04355767
Discussing COVID-19 Vaccines in Private Facebook Groups
George Washington University
NCT05422898
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
Wake Forest University Health Sciences
NCT04540484
Leveraging Social Networks to Increase COVID-19 Testing Uptake
New York State Psychiatric Institute
NCT04873401
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05780463
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Connecticut Children's Medical Center
NCT04838834
Saliva as Source of Detection for SARS-CoV-2
National Institutes of Health Clinical Center (CC)
NCT04424446
Prophylaxis and Treatment of COVID-19
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT04844541
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
Abbott Rapid Dx
NCT06127108
COVID-19 in Patients With HIV
University of Missouri-Columbia
NCT04333953
COVID-19 SAFE Enrollment
University of Pennsylvania
NCT04506268
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
Covis Pharma S.à.r.l.
NCT04377711
Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
University of Colorado, Denver
NCT04542421
Asymptomatic SARS-CoV-2 Detection in Children
University of Calgary
NCT04853316
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05780281
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
ViroGates A/S
NCT07466524
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Vir Biotechnology
NCT04779879
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
Mayo Clinic
NCT04884477
Audio Data Collection for Identification and Classification of Coughing
HealthMode
NCT04326309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.